Depression and anxiety disorders during pegylated interferon treatment in patients with chronic hepatitis B
Makaleler > Tam Makale · 2017
Yazarlar: Özen ÖNEN SERTÖZ, Özlem KUMAN TUNÇEL, Meltem TAŞBAKAN, Hüsnü PULLUKÇU, İsabel Raika DURUSOY, Tansu YAMAZHAN, Hayriye ELBİ
PSYCHIATRY AND CLINICAL PSYCHOPHARMACOLOGY, SCI Expanded İndekslerine Giren Dergi, Uluslararası, 2017, cilt 27, ss 47-53
DOI: 10.1080/24750573.2017.1293251
Özet
Objectives: Interferon (IFN) treatment has many neuropsychiatric side effects such as depression and anxiety disorder. Although untreated depression is a major contributor to dosage reduction or premature discontinuation of the IFN treatment, it is found that depressive symptoms among patients undergoing hepatitis C virus (HCV) treatment are commonly overlooked during routine clinical interviews. Besides depression, anxiety disorders are shown to affect adherence to pegylated IFN (Peg-IFN) treatment in patients with hepatitis C. Despite the occurrence of neuropsychiatric side effects of IFN treatment being widely reported in patients with hepatitis C, there are few studies studying patients infected with hepatitis B virus (HBV). The aim of this prospective study was to evaluate the incidence and risk factors of depressive and anxiety disorders that occur during Peg-IFN treatment of patients with HBV.